Wednesday, May 31, 2017

Another report on autism

Game changer for autism:
"Suramin was originally developed as a cure for sleeping sickness, a parasitic disease spread by the tsetse fly in sub-Saharan Africa.
First tested on mice in 2013, this is the first time suramin has been administered to children.
For Naviaux, the challenge now is to widen his research to a bigger sample testing size. “This work is new and this type of clinical trial is expensive,” he said. “We did not have enough funding to do a larger study. And even with the funding we were able to raise, we had to go $500,000 in debt to complete the trial.”"
Another report
"Furthermore, all of the children who were administered suramin experienced a rash, an alarming side effect. And although the children showed remarkable positive cognitive and emotional improvements, the effects were only temporary. After three weeks, the children all regressed back to the norm. Even so, the study warrants further research."
See also N of One: Autism Research Foundation Interviews Robert Naviaux, MD PhD on Suramin & Autism Trial May 2017 

No comments: